Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In Phase 3 studies: Participants without diabetes taking orforglipron lost approximately 9% to 10% of body weight over roughly 36 to 40 weeks Participants with type 2 diabetes generally lost around 7% to 8% By comparison, Wegovy's landmark STEP trials reported approximately 14.9% average weight loss over 68 weeks
Across studies with sufficient initial weight loss for meaningful interpretation, defined here as over 3 kg, the weight regained at or around 12 weeks post-cessation ranged from approximately 10 to 80% of the treatment-induced weight loss
Also, a peer-reviewed study published by earlier this year by the research journal Obesity indicates that only 40% of obese patients taking semaglutide-based GLP-1 products were persistent at one year
Their clinical advantage in managing type 2 diabetes and obesity has positioned them strongly in treatment guidelines
